Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1582313 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $63.10Day −2.83%Mkt cap $6.1B1Y +104.4%Off 52W high −13.2%Vol (1Y) 60.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,946 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.6% of sh out |
| Days to cover3.6d |
| 13F net flow (QoQ)+12.43% |
| Top-10 13F concentration47.2% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$383.2M |
| ROE−51.8% |
| Net margin−4612.1% |
| ROIC−59.3% |
| Sales growth 3Y−7.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+40.8% |
| 1Y+104.4% |
| 3Y+70.9% |
| 5Y+258.3% |
| 10Y+725.9% |
| Since incept. (ann.)+16.5% |
Total return through 2026-07-29 · series begins 2014-11-05. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)60.6% |
| Ann. volatility (3Y)49.0% |
| Sharpe (1Y)1.44 |
| Sharpe (3Y)0.60 |
| Max drawdown (1Y)−18.4% |
| Max drawdown (3Y)−43.6% |
| Beta (3Y vs SPY)0.04 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 10.8M | $629M | — | +21.3% |
| Avoro Capital Advisors LLC | 5.8M | $336M | — | +6.5% |
| BlackRock, Inc. | 5.6M | $328M | — | +10.6% |
| WELLINGTON MANAGEMENT GROUP LLP | 4.8M | $281M | — | +1.4% |
| Driehaus Capital Management LLC | 4.5M | $261M | — | −1.0% |
| Polar Capital Holdings Plc | 4.4M | $256M | — | +78.7% |
| JANUS HENDERSON GROUP PLC | 4.2M | $243M | — | +2.3% |
| Capital International Investors | 2.7M | $156M | — | −21.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (100,364,715) exceed the cover-page shares-outstanding count for this quarter (83,190,316, as of 2026-02-23) by more than securities-lending double counting can explain (FINRA short interest 4,149,067 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$1.17 | — | $0 | −100.0% |
| 2025-12-31 | 2026-02-26 | — | — | $0 | — |
| 2025-09-30 | 2025-11-03 | −$1.15 | — | $0 | — |
| 2025-06-30 | 2025-08-11 | −$1.07 | — | $0 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
